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Introduction
Patients with pediatric rheumatic disease rarely develop
pulmonary arterial hypertension (PAH), and the expected
prognosis had been very poor. With the advancement of
oral medicine for PAH in recent years, we can expect
better prognosis of these patients. For this purpose, early
diagnosis and interventions are essential.
Objectives
We report on a 14 years old girl suffering from PAH
with overlap syndrome (SLE and systemic sclerosis loca-
lised type).
Methods
At age 7, she developed autoimmune hepatitis. She was
diagnosed with lupus nephritis (class II + V) from
pathological finding and pulmonary hypertension (PH)
at age 10, and treated with immunosuppressive therapy
(methylprednisolone pulse therapy, cyclophosphamide
pulse therapy and mycophenolate mofetil) and home
oxygen therapy at night. Comprehensive examination
about PH was carried out at age 12.
Results
In ultra sound, tricuspid regurgitation and increased
pressure gap of tricuspid valve are observed and esti-
mated right ventricular systolic pressure was 60 mmHg.
In right heart catheterization, mean pulmonary artery
pressure at rest was 43 mmHg and pulmonary vascular
resistance was 711 dyne·sec·10-5. We had diagnosed her
as overlap syndrome (SLE and systemic sclerosis loca-
lized type) with PAH, and started combination therapy
of sildenafil and ambrisentan. We confirmed the
improvement of PAH by right heart catheterization ;
mean pulmonary artery pressure (23 mmHg) and pul-
monary vascular resistance (296 dyne·sec·10-5).
Conclusion
Considering the obvious limitations of our single case
report, we observed a good short term outcome of pedia-
tric PAH-CTD. In order to obtain effects of oral medi-
cine for PAH, it is important to start the intervention at
early stage of this disease. It may be useful to plan
screening tests (cardiac ultrasonography, pulmonary func-
tion test) on a regular basis for patients with pediatric
rheumatic disease at high risk of developing PAH.
Disclosure of interest
None declared.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-P257
Cite this article as: Yamaguchi et al.: PReS-FINAL-2267: Successful
treatment of pulmonary arterial hypertension associated
with connective tissue disease (PAH-CTD) with combination therapy of
sildenafil and ambrisentan: a case report. Pediatric Rheumatology 2013 11
(Suppl 2):P257.Division of Allergy and Rheumatology, St. Luke’s International Hospital,
Tokyo, Japan
Yamaguchi et al. Pediatric Rheumatology 2013, 11(Suppl 2):P257
http://www.ped-rheum.com/content/11/S2/P257
© 2013 Yamaguchi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
